Raloxifen: A selective estrogen receptor modulator;Le raloxifene: Un modulateur selectif du recepteur aux oestrogenes

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 28, Issue 8, 1999, Pages 788-799

  Van Den Brule F A ^a   Kalbus, M F ^a   Gaspard, U J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Menopause; Prevention; Raloxifene; SERMs

Indexed keywords

ESTRADIOL; FULVESTRANT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ANTIESTROGEN; ESTROGEN RECEPTOR;

CANCER PREVENTION; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; BREAST TUMOR; DRUG EFFECT; FEMALE; POSTMENOPAUSE OSTEOPOROSIS;

BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0033395918     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, Magee DE, Termine JD, Bryant HU. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci 1995; 761: 355-60
2. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR, Falcone JF, Clemens JA. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 1984; 27: 1057-66.
3. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Nat Acad Sci USA 1997; 94: 14105-10.
4. Palkowitz AD, Glasebrook AL, Thrasher KJ, Hauser KL, Short LL, Phillips DL, Muehl BS, Sato M, Shetler PK, Cullinan GJ, Pell TR, Bryant HU. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b] thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem, 1997; 40: 1407-16.
5. Black LJ, Goode RL. Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms. Endocrinology 1981; 109: 987-9.
6. Jordan VC, Gosden B. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology 1983; 113: 463-8.
7. Glasebrook AL, Phillips DL, Sluka JP. Multiple binding sites for the anti-estrogen raloxifene. J Bone Min Res 1993; 8 (Suppl. 1): S268.
8. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-8.
9. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53.
10. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJ, Glasebrook AL, Termine JD. Estrogen and raloxifene stimulate transforming growth factor-β3 gene expression in rat bone: a potential mechanism for estrogen-or raloxifene-mediated bone maintenance. Endocrinology 1996; 137: 2075-84.
11. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996; 273: 1222-5.
12. Centrella M, Horowitz MC, Wozney JM. Transforming growth factor β-gene family members and bone. Endocrine Rev 1993; 15: 27-59.
13. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Correction: raloxifene response needs more than an element [letter]. Science 1997; 275: 1249.
14. Shiau SP, Glasebrook A, Hardikar SD, Yang NN, Hershberger CL. Activation of the human estrogen receptor by estrogenic and antiestrogenic compounds in Saccharomyces cerevisiae: a positive selection system. Gene 1996; 179: 205-10.
15. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277: 1508-10.
16. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257: 88-91.
17. Sato M, Kim J, Bryant HU. Estrogen, tamoxifen, raloxifen and nafoxidine have different effects on ovariectomized rats and on rat osteoclasts. J Bone Miner Res 1994; 9 (Suppl I): S197.
18. Fiorelli G, Martineti V, Gori F, Benvenuti S, Frediani U, Formigli L, Zecchi S, Brandi ML. Heterogeneity of binding sites and bioeffects of raloxifene on the human leukemic cell line FLG 29.1. Biochem Biophys Res Commun 1997; 240: 573-9.
19. Arjmandi BH, Salih MA, Hollis BW, Kalu DN. In vivo effect of 17β-estradiol on on intestinal calcium absorbtion. J Bone Miner Res 1993; 8 (Suppl I): S271.
20. Magee DE, Cole HW, Brown CE, Bryant HU. Raloxifen and estrogen retain anti-osteopenic activity in ovariectomized rats fed a low calcium diet. J Bone Miner Res 1994; 9 (Suppl I): S198.
21. Bryant HU, Magee DE, Cole HW, Chandrasekhar S, Hsuing HM, Heiman ML, Sato M. Beneficial effects of ethynilestradiol and raloxifene in the ovariectomized rat are dependent on an intact pituitary. J Bone Miner Res 1994; 9 (Suppl I): S135.
22. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Nat Acad Sci USA 1992; 89: 6983-7.
23. Dodge JA, Lugar CW, Cho S, Short LL, Sato M, Yang NN, Spangle LA, Martin MJ, Phillips DL, Glasebrook AL, Osborne JJ, Frolik CA, Bryant HU. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol 1997; 61: 97-106.
24. Gordon MN, Mobbs CV, Finch CE. The antiestrogen LY117018 blocks effects of estradiol on pituitary glucose-6-phosphate dehydrogenase specific activity and on serum LH. Neuroendocrinology 1985; 40: 381-4.
25. Ortmann O, Emons G, Knuppen R, Catt KJ. Inhibitory actions of keoxifene on luteinizing hormone secretion in pituitary gonadotrophs. Endocrinology 1988; 123: 962-8.
26. Ortmann O, Sturm R, Knuppen R, Emons G. Weak estrogenic activity of phenol red in the pituitary gonadotroph: re-evaluation of estrogen and antiestrogen effects. J Steroid Biochem 1990; 35: 17-22.
27. Awata S. Effects of RU486 and keoxifene on the dispersed pituitary cells of pregnant rats. Jpn J Fertil Steril 1992; 37: 22-8.
28. Simard J, Labrie F. Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. Mol Cell Endocrinol 1985; 39: 141-4.
29. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new anti-estrogen, keoxifene LY156758, on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983; 32: 2869-75.
30. Simard J, Labrie C, Merand C, Dufour JM, Levesque C, Labrie F. Pure antagonostic effect of a new steroidal antiestrogen in rat anterior pituitary cells in culture and in mouse uterus. Ann NY Acad Sci 1990; 595: 425-7.
31. Simard J, Hubert JF, Hosseinzadeh T, Labrie F. Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture. Endocrinology 1986; 119: 2004-11.
32. Martinoli MG, Veilleux R, Pelletier G. Effects of triiodothyronine, dexamethasone and estradiol-17 beta on GH mRNA in rat pituitary cells in culture as revealed by in situ hybridization. Acta Endocrinol (Copenh) 1991; 124: 83-90.
33. Meisl RL, Dohanich GP, McEwens BS, Pfaff DW. Antagonism of sexual behavior in female rats by ventromedial hypathalamic implants of antiestrogen. Neuroendocrinology 1987; 45: 201-7.
34. Draper MW, Flowers DE, Neild JA, Huster WJ, Zerbe RL. Antioestrogneic properties of raloxifene. Pharmacology 1995; 50: 209-17.
35. Baker VL, Draper M, Paul S, Allerheiligen S, Giant M, Shifren J, Jaffe RB. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 1998; 83: 6-13.
36. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983; 32: 1031-6.
37. Jordan VC, Allen KE, Dix CJ. Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 1980; 64: 745-59.
38. Fuchs-Young R, Magee DE, Cole HW, Short L, Glasebrook AL, Rippy MK, Termine JD, Bryant HU. Raloxifene is a tissue-specific anti-estrogen that blocks tamoxifen or estrogen-stimulated uterotrophic effects. Endocrinology 1995; 136 (suppl.): 57.
39. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93: 63-93.
40. Black LJ, Jones CD, Clarck JH. LY156758: a unique antiestrogen displaying high affinity for estrogen receptors, negligible estrogenic activity and near-total estrogen antagonism in vivo. Breast Cancer Res Treat 1982; 2: 279.
41. Ashby J, Odum J, Foster JR. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regul Toxicol Pharmacol 1997; 25: 226-31.
42. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996; 10: 905-12.
43. Boss SM, Huster WJ, Neild JA, Giant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997; 177: 1458-64.
44. Pellerin I, Vuillermoz C, Jouvenot M, Royer M, Ordener C, Marechal G, Adessi G. Superinduction of c-Fos gene expression by estrogen in cultured guinea pig endometrial cells requires priming by a cycloheximide-dependent mechanism. Endocrinology 1992; 131: 1094-100.
45. Ishihara S, Taketani Y, Mizuno M. Inhibitory effects of estradiol on glycogen synthesis in primary cell cultures of human endometrium. Endocrinol Jpn 1988; 35: 691-6.
46. Fournier B, Haring S, Kaye AM, Somjen D. Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones. J Endocrinol 1996; 150: 275-85.
47. Palsey JN. Effects of antiestrogen treatment on estradiol-enhanced chlamydial genital infection in female guinea pigs. Proc Soc Exp Biol Med 1992; 200: 140.
48. Sundstrom S, Komm BS, Xu Q, Boundy V, Lyttle CR. The stimulation of uterine complement C3 gene expression by antiestrogens. Endocrinol 1990; 126: 1449-56.
49. Knecht M, Brodie AMH, Catt KJ. Aromatase inhibitors prevent granulosa cell proliferation: an obligatory role for estrogens in luteinization hormone receptor expression. Endocrinology 1985; 117: 1560-1.
50. Veldhuis JD, Azimi P, Juchter D, Germey J. Mechanisms subserving the bipotential actions of estrogen on ovarian cells: studies with a selective anti-estrogen, LY156758, and the sparingly metabolizable estrogen agonist, moxestrol. J Steroid Biochem 1986; 5: 977-82.
51. Iyo M. The effect of FSH, diethylstilboestrol and 2-hydroxyestradiol on steroidogenesis in cultured rat granulosa cells. Jpn J Fertil Steril 1991; 36: 513-9.
52. Kessel B, Hsueh AJW. Keoxifene (LY156758) inhibits follicle-stimulating hormone-induced differenciation of cultured rat granulosa cells. Life Sci 1987; 40: 1089-97.
53. Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F. Characteristics of the biphasic action of androgens and of the potent anti-proliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 1991; 51: 5165-70.
54. Mariotti A, Durham J, Frederickson R. Actions and interactions of estradiol and retinoid acid in mouse anterior prostate gland. Biol Reprod 1987; 37: 1023-35.
55. Neubauer BL, Biser P, Jones CD, Mariotti A, Hoover DM, Thornton T, Thornton MO, Goode R. Antagonism of androgen and estrogen effects in guinea pig seminal vesicle epithelium and fibromuscular stroma by keoxifene (LY156758). Prostate 1989; 15: 273-86.
56. Chou YC, Iguchi I, Bern HA. Effects of antiestrogens on adult and neonatal mouse reproductive organs. Reprod Toxicol 1992; 6: 439-46.
57. Neubauer BL, Best KL, Clemens JA, Gates CA, Goode R, Jones CD, Laughlin ME, Shaar CJ, Toomey RE, Hoover DM. Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat. Prostate 1993; 23: 245-62.
58. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987; 10: 31-5.
59. Feldmann S, Minne HW, Parvizi S, Pfeifer M, Lempert UG, Bauss F, Ziegler R. Antiestrogen and antiandrogen administration reduce bone mass in the rat. Bone Miner 1989; 7: 245-54.
60. Sato M, McClintock C, Kim J, Turner CH, Bryant HU, Magee D, Slemenda CW. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res 1994; 9: 715-24.
61. Sato M, Kim J, Short LL, Slemenda CW, Bryant HU. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther 1995; 272: 1252-9.
62. Sato M. Comparative x-ray densitometry of bones from ovariectomized rats. Bone 1995; 17: 157S-62S.
63. Bryant HU, Turner CH, Frolik CA, Magee DE, Cole HW, Brown CE, Rippy MK, Sato M. Long term effects of raloxifene (LY139478 HCI) on bone, cholesterol and uterus in ovariectomized rats. Bone 1995; 16 (Suppl.): 116S.
64. Curiel MD, Calero JA, Guerrero R, Gala J, Gazapo R, de la Piedra C. Effects of LY-117018 HCI on bone remodeling and mineral density in the oophorectomized rat. Am J Obstet Gynecol 1998; 178: 320-5.
65. Evans G, Bryant HU, Magee D, Sato M, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994; 134: 2283-8.
66. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994; 135: 2001-5.
67. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in serum cholesterol and osteocalcin, and urinary pyridinium crosslinks in ovariectomized rats: reversal by raloxifene or ethynylestradiol. J Bone Miner Res 1994; 9 (Suppl I): S328.
68. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCI, tamoxifen, estrogen, and alendronate. Bone 1996; 18: 621-7.
69. Bowman AR, Sass DA, Marshall I, Ma YF, Liang H, Jee WS, Epstein S. Raloxifene analog (LY117018 HCL) ameliorates cyclosporin A-induced osteopenia in oophorectomized rats. J Bone Miner Res 1996; 11: 1191-8.
70. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and the risk of cardiovascular disease: the Framingham study. Ann Med Interne 1976; 85: 447-52.
71. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
72. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641-6.
73. Gaspard UJ, Gottal J-M, van den Brûle FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 1995; 21: 171-8.
74. Collins P. Vascular aspects of oestrogen. Maturitas 1996; 23: 217-26.
75. Kauffman RF, Bensch WR, Roudebush RE, Cole HW, Bean JS, Phillips DL, Monroe A, Cullinan GJ, Glasebrook AL, Bryant HU. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther 1997; 280: 146-53.
76. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997; 96: 1964-9.
77. Zuckerman SH, Bryan-Poole N. Inhibition of LDL oxidation and myeloperoxidase-dependent tyrosyl radical formation by the selective estrogen receptor modulator LY 139481 HCI. Atherosclerosis 1996; 126: 65-75.
78. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998; 83: 721-6.
79. Wakeling AE, Valcaccia B, Newboult E, Green LR. Non-steroidal antioestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984; 20: 111-20.
80. Sato M, Glasebrook AL, Bryant U. Raloxifene: a selective oestrogen receptor modulator. J Bone Miner Met 1995; 12 (suppl II): S9-S20.
81. Wiznitzer I, Benz C. Tamoxifen vs. LY156758 for treatment of human breast and prostate cancer in vitro. Breast Cancers Res Treat 1983; 3: 305.
82. Labrie F, Poulin R, Simard J, Zhao HF, Labrie C, Dauvois S, Dumont M, Hatton AC, Poirier D, Merand Y. Interactions between estrogens, androgens, progestins and glucocorticoids in ZR-75-1 human breast cancer cells. Ann NY Acad Sci 1990; 595: 130-48.
83. Labrie F, Veilleux R, Fournier A. Glucocorticoids stimulate the growth of mouse mammary carcinoma Shionogi cells in culture. Molec Cell Endocrinol 1988; 58: 207-11.
84. Thompson EW, Reich R, Shima TB, Albini A, Graf J, Martin GR, Dickson RB, Lippman ME. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antioestrogens. Cancer Res 1988; 48: 6764-8.
85. Wakeling AE, Valcaccia B. Antioestrogenic and antitumor activities of a series of non-steroidal antioestrogens. J Endocr 1983; 99: 455-64.
86. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987; 47: 4020-4.
87. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996; 88: 123-5.
88. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 1988; 45: 344-5.
89. Nicholson RI, Getting KE, Gee J, Walker KJ. Actions of oestrogens and antiestrogens on rat mammary gland development: relevance to breast cancer prevention. J Steroid Biochem 1988; 30: 95-103.
90. Kleinberg DI, Todd J, Babitski G. Inhibition by estradiol of the lactogenic effect of prolactin in primate mammary tissue: reversal by antiestrogens LY156758 and tamoxifen. Proc Nat Acad Sci USA 1983; 80: 4144-8.
91. Daniel CW, Silberstein G, Strickland P. Direct action of 17β-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Res 1987; 47: 6052-7.
92. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 1990; 11: 578-610.
93. White INH, DeMatteis R, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH. Genetoxic potential of tamoxifen and analogs in female Fisher F344/N rats, DBA/2 and C57BL/6 mice and human MCL5 cells. Carcinogenesis 1992; 13: 2197-203.
94. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project. J Nat Cancer Inst 1994; 86: 527-37.
95. Gottardis MM, Ricchio ME, Satyaswaroop PG. Effect of steroidal and non-steroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 1990; 50: 3189-92.
96. Jordan VC, Gottardis MM, Satyaswaroop PG. Tamoxifen-stimulated growth of endometrial carcinoma. Ann NY Acad Sci 1991; 622: 439-46.
97. Neubauer BL, Best KL, Counts DF, Goode RL, Hoover DM, Jones CD, Sarosdy MF, Shaar CJ, Tanzer LR, Merriman RL. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. Prostate 1995; 27: 220-9.
98. Liehr JG, Sirbasku DA, Jurka E. Inhibition of estrogen-induced renal carcinogenesis in male Syrian hamsters by tamoxifen without decreases in DNA adduct levels. Cancer Res 1988; 48: 779-83.
99. Liehr JG, Folse DS, Roy D. Lack of effectiveness of antiestrogens RU39,411 or keoxifene in the prevention of estrogen-induced tumors in Syrian hamsters. Cancer Lett 1987; 64: 23-9.
100. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCI: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835-42.
101. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7.
102. Ott SM, Oleksik A, Lu Y, Harper K, Lips P. Bone hitomorphometric results of a 2-year randomized, placebo-controlled trial of raloxifene in postmenopausal women. Bone 1998; 23 (S5): S295.
103. Gunness M, Prestwood K, Lu Y, Muchmore DB, Raisz L. Histomorphometric, bone marker, and bone mineral density response to raloxifene HCI and Premarin in postmenopausal women. The Endocrine Society, 79th Annual Meeting Program 1997: 67.
104. Goldstein S, Srikanth R, Parsons A, Londono J, Kenemans P, Wilkie J, Walsh B, Shah A, Scheele WH. Effects of raloxifene on the endometrium in healthy postmenopausal women. Menopause 1998; 5: 71.
105. Shah AS, Scheele WH, Glant MD, Fugère P. Raloxifene HCI is not stimulatory in the endometrium as assessed by the Blaunstein criteria and estrogenicity scoring system. ACOG, 46th Annual Clinical Meeting Abstract Book 1998: 66.
106. Heaney RP, Draper MW. Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab 1997; 82: 3425-9.
107. Ettinger B, Black D, Cummings S, Genant H, Glüer C, Lips P, Knickerbocker R, Eckert S, Nickelsen T, Mitlack B, for the MORE Study Group. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses. Osteoporosis Int 1998; 8: S3.
108. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189-97.
109. Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A, Morrow M, Norton L. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in 12,000 postmenopausal women. Proc Am Soc Clin Oncol 1998; 17: xx.
110. Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, Black DM, Nickelsen T, Glusman J, Krueger K. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two year findings from the multiple outcomes of raloxifene evaluation (MORE) trial. Proc Am Soc Clin Oncol 1998; 17: 3.
111. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Ass 1998; 279: 1445-51.
112. Cohen F, Watts S, Beymer K. Vaginal complaints in healthy postmenopausal women: data from a 3-year trial comparing raloxifene with conjugated estrogens or placebo. Menopause 1998; 5: 283.
113. Evista™, Notice scientifique. 1998.
114. Davies GC, Huster WJ, Lu Y, Plouffe LJ, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93: 558-65.
115. Lu Y, Cohen F, Lakshmanan M. Characterization of hot flashes during raloxifene therapy: analyses of adverse event reports from an integrated placebo-controlled database. Menopause 1998; 5: 85.
116. Glusman JE, Huster WJ, Paul S. Raloxifene effects on vasomotor and other climateric symptoms in postmenopausal women. ACOG, 46th Annual Clinical Meeting Abstract Book 1998: 16.